Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer.
Palakurthi B, Fross SR, Guldner IH, Aleksandrovic E, Liu X, Martino AK, Wang Q, Neff RA, Golomb SM, Lewis C, Peng Y, Howe EN, Zhang S.
Palakurthi B, et al. Among authors: neff ra.
Nat Commun. 2023 Apr 13;14(1):2109. doi: 10.1038/s41467-023-37727-y.
Nat Commun. 2023.
PMID: 37055410
Free PMC article.